Core Insights - Zhangjiang is becoming a key location for global pharmaceutical and medical device companies, with over 30 out of 38 external licensing transactions in Shanghai in 2024 originating from Zhangjiang, accounting for over 80% of the city's total [1] Industry Growth - The biopharmaceutical industry in Pudong has shown consistent growth, with a scale of 338.2 billion yuan in 2022, 378 billion yuan in 2023, and projected to reach 410 billion yuan in 2024. The total biopharmaceutical industry scale in Shanghai is expected to be 984.7 billion yuan in 2024, with Pudong accounting for 41.6% [1] Workforce Development - The total number of biopharmaceutical professionals in Pudong is steadily increasing, with 129,100 in 2023 (45.9% of the city) and 129,900 in 2024 (46.0% of the city). The new talent entry rate for 2024 is 16.3%, while the turnover rate is 15.6%, indicating a stable workforce with some expansion [1] Educational Background - The proportion of PhD holders in Pudong's biopharmaceutical sector is 5.0%, surpassing the average of 2.6% in three leading industries. In Zhangjiang, this figure is even higher at 5.9%. In the pharmaceutical R&D services sector, the proportion of master's and doctoral talent is 36.7%, the highest among sub-industries [1] Youth Talent Initiatives - Over 60% of the workforce in the biopharmaceutical industry is under 40 years old. The "two 1 million" policy, which includes 1 million square meters of low-rent youth apartments and 1 million square meters of low-rent entrepreneurial space, aims to attract more young talent to the industry [2] Talent Attraction Strategies - Pudong is utilizing multiple channels to attract talent, including global university talent programs and international talent stations. The trend of returning overseas students is evident, with the proportion of returning students expected to rise from 2.5% in 2024 to 3.1% in 2025 [2] Talent Demand and Salary Trends - The demand for high-end talent is increasing, particularly in emerging fields such as immunology, cell therapy, antibody/RNA/nucleic acid drug development, AI integration, and biosynthesis technology. The starting salary for new PhD graduates in 2025 is expected to increase more than for other educational levels, driven by industry needs and policy support [2]
浦东汇聚超14万生物医药专业人才 张江正成为药械企业全球化“必选地”之一
Jie Fang Ri Bao·2025-12-07 02:34